Full Press Release Details
argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis.
ARGX
argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis
Key Takeaway: argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis